What the Compound Is
AOD-9604 is a synthetic peptide covering amino acids 177 through 191 of human growth hormone, with an added tyrosine at one end. The idea behind the design is straightforward. Growth hormone's effects on fat metabolism (lipolysis, the release and oxidation of stored fat) and its growth-promoting effects run through different signaling paths. Researchers isolated the fragment responsible for the lipolytic signal, hoping to keep the fat-metabolism activity while leaving growth and IGF-1-mediated effects out.
The Animal Research
In animal models, the fragment showed clear lipolytic activity, reducing body fat gain without affecting food intake or the growth measures that full growth hormone changes. Those results drove the compound into human development in the early 2000s under Metabolic Pharmaceuticals, an Australian company.
The Human Trial Record
This is the part that gets edited out of most product listings. Metabolic ran a series of human trials, including a phase 2b obesity trial in the mid-2000s. The trial tested whether daily AOD-9604 produced meaningful weight loss in people with obesity over several months. It did not separate from placebo. Weight loss in the treatment arms was not significantly different from the placebo arm, and development for obesity was discontinued.
The trials did produce two observations that keep the compound in research discussions. The compound was well tolerated at the doses tested, and it showed no growth-promoting or IGF-1-elevating signal, which means the design goal of separating the two activities was achieved. The failed part was efficacy against the clinical endpoint.
Where the Research Stands Now
After the obesity program ended, laboratory work explored other directions, including effects on cartilage and joint tissue, and the compound found its way into the grey-market research peptide world, where it is now marketed far more confidently than the published record supports.
For someone evaluating AOD-9604 research claims today, the honest framing is this: a mechanistically rational design, confirmed animal activity, a clean human safety signal at tested doses, and a demonstrated failure to produce weight loss in a properly controlled human trial. Each part of that sentence matters, and product pages usually keep only the first three.
The Broader Lesson
AOD-9604 is a useful case study for reading peptide research claims generally. The compound has real published science behind it, which is more than can be said for many grey-market peptides. It still failed its central human trial. Published research exists on a spectrum, and the endpoint, the population, and the outcome all matter as much as the fact that a study was run. Compounds with no human data at all deserve even more skepticism than a compound with a documented miss.
Important Note
This article is for educational and research reference purposes only. AOD-9604 has no approved human therapeutic use, and nothing here constitutes medical advice.